Filing Analysis
OnKure Therapeutics held its 2026 Annual Meeting of Stockholders on June 3, 2026, resulting in the election of three Class II directors, the ratification of KPMG LLP as the auditor, and the approval of an amended 2024 Equity Incentive Plan.
🚩 Red Flags
- Dilution: The increase in shares reserved for the Equity Incentive Plan (3.2M shares) will result in shareholder dilution.
📋 Key Facts
- Stockholders approved the Amended and Restated 2024 Equity Incentive Plan, which includes a one-time increase of 3,231,638 shares (approx. 8% of outstanding shares).
- The Equity Incentive Plan amendment removes the previous annual limit of 2,407,100 shares while maintaining a 5% annual 'evergreen' increase based on outstanding shares.
- R. Michael Carruthers, Valerie M. Jansen, M.D., Ph.D., and Edward T. Mathers were elected as Class II directors until 2029.
- KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
OnKure Therapeutics, Inc. reported its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished under Item 2.02 of the Form 8-K.
📋 Key Facts
- Financial results cover the quarter ended March 31, 2026.
- The report was filed on May 5, 2026.
- The information is furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Jason Leverone, Chief Financial Officer, signed the filing.
OnKure Therapeutics announced a $150 million private placement of common stock and pre-funded warrants at $4.15 per share. Simultaneously, the company disclosed a major strategic pivot, discontinuing independent development of its lead clinical asset OKI-219 to focus on next-generation candidates with IND filings planned for 2027.
🚩 Red Flags
- Significant dilution from the issuance of over 36 million shares/equivalents.
- Strategic abandonment of the current lead clinical asset (OKI-219) for independent development.
- Long lead time for new pipeline assets, with IND applications not expected until the first half of 2027.
📋 Key Facts
- Entered into a Securities Purchase Agreement for approximately $150 million in gross proceeds.
- Issuing 26,713,636 shares of Class A common stock and 9,430,959 pre-funded warrants at $4.15 per unit.
- Lead investor AI Biotechnology LLC granted a board nominee right; Dr. Liam Ratcliffe appointed to the Board.
- Discontinuing independent clinical development of OKI-219 despite completing enrollment in Phase 1a/1b dose escalation.
- Shifting focus to next-generation PI3Kα pan-mutant programs OKI-345 and OKI-355, with IND applications expected in H1 2027.
- Executive officers and directors entered into 180-day lock-up agreements.
OnKure Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal disclosure of the company's year-end performance via a press release attached as an exhibit.
📋 Key Facts
- The report was filed on March 12, 2026, covering the period ended December 31, 2025.
- The filing includes Item 2.02 (Results of Operations and Financial Condition).
- Jason Leverone, Chief Financial Officer, signed the filing.
- The company is classified as an emerging growth company.